




















Pipeline

A number of targeted anticancer compounds are now in clinical testing through our own product programs and those of our partners. Information on the relevant subtypes of each cancer can be found in the discussion of each compound.

13 COMPOUNDS IN CLINICAL TESTING

IMGN853 Ovarian, endometrial	 
IMGN529 Non-Hodgkin lymphoma	 
IMGN289 Head, neck, lung, breast	 
IMGN779 AML	
Kadcyla® HER2+ mBC 2nd-line	    
HER2+ mBC 1st line	   

others	Preclinical	Phase I	Phase II
	Pivotal/ Phase III		
HER2+ gastric	Preclinical	Phase I	Phase II
	Pivotal/ Phase III		
SAR3419 DLBCL	Preclinical	Phase I	Phase II
SAR650984* Multiple myeloma	Preclinical	Phase I	Phase II
SAR566658 Solid tumors	Preclinical	Phase I	
SAR408701 Solid tumors	Preclinical	Phase I	
BT-062 Multiple myeloma	Preclinical	Phase I	Phase II
Breast, bladder	Preclinical	Phase I	
BAY 94- 9343 Mesothelioma, ovarian	Preclinical	Phase I	
AMG 595 Glioblastoma	Preclinical	Phase I	
AMG 172 Kidney	Preclinical	Phase I	
LOP628 cKIT+ cancer	Preclinical	Phase I	
Novartis 2 Mediastinal	Preclinical		



Kadcyla® is a registered trademark of Genentech, a member of the Roche Group.

* Therapeutic antibody

mBC: metastatic breast cancer

BC: breast cancer

DLBCL: diffuse large B-cell lymphoma

Based on information on clinicaltrials.gov or other public disclosures.

Last updated: January 15, 2015

